A prospective study of the treatment of high-grade histology non-Hodgkin's lymphoma involving the gastrointestinal tract

Eur J Cancer Clin Oncol. 1985 Oct;21(10):1195-200. doi: 10.1016/0277-5379(85)90015-x.

Abstract

Thirty-six patients presenting with stage II-IV primary gastrointestinal non-Hodgkin's lymphoma of high-grade pathology were treated in a prospective study from 1975 to 1983 with combined modality therapy. A complete response rate of 56% was obtained and the overall 5-yr survival rate was 36%. The 5-yr relapse-free survival rate of the complete remitters was 79%. Multivariate analysis revealed that the remission achieved (P less than 0.001) and the completeness of primary surgery (P = 0.018) would reliably predict the duration of overall survival. The finding of diffuse histiocytic histology (Rappaport) predicted longer relapse-free survival. The majority of deaths were related to intra-abdominal complications and not to disseminated lymphoma. Gastrointestinal tract non-Hodgkin's lymphoma of high-grade pathology of all stages is curable with a combination of chemotherapy and radiotherapy following surgery to remove as much macroscopic disease as is possible.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Combined Modality Therapy
  • Doxorubicin / therapeutic use
  • Female
  • Gastrointestinal Neoplasms / drug therapy*
  • Gastrointestinal Neoplasms / mortality
  • Gastrointestinal Neoplasms / radiotherapy
  • Humans
  • Lymphoma / drug therapy*
  • Lymphoma / mortality
  • Lymphoma / radiotherapy
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Procarbazine / therapeutic use
  • Prospective Studies
  • Vincristine / therapeutic use

Substances

  • Procarbazine
  • Vincristine
  • Doxorubicin

Supplementary concepts

  • VAP combination